If you have been reading about carcinogenicity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
== Clinical use == European Association of Urology (EAU) guidelines recognise that PSMA can provide accurate staging, however there is a lack of outcome data to inform further management. The American Society of Clinical Oncology (ASCO) guidelines for imaging of advanced prostate cancer also recommend PSMA imaging (among other PET radiopharmaceuticals), while acknowledging that these are not FDA approved and therefore limited to a clinical trial or other controlled research setting. Although PSMA PET imaging has shown clear superiority over conventional CT and bone scans for detecting prostate cancer, comparative studies assessing different PSMA ligands, such as 68Ga-PSMA-11 and 18F-DCFPyL, remain limited. A 2024 overview of reviews published in Seminars of Nuclear Medicine concluded that while evidence gaps remain for some outcomes and most systematic reviews are at high or unclear risk of bias, the evidence base is broadly supportive of 18F PSMA PET/CT in patients with high-risk prostate cancer or biochemical recurrence
==== Impact of UDI ==== The years following Rhodesia's UDI saw an unfolding series of economic, military, and political pressures placed on the country that eventually brought about majority rule, a totality of these factors rather than any one the reason for introducing change. In 2005, a conference at the London School of Economics that discussed Rhodesia's independence concluded that UDI was sparked by an existing racial conflict complicated by Cold War intrigues. Critics of UDI maintained that Ian Smith intended to safeguard the privileges of an entrenched colonial ruling class at the expense of the impoverished black population. Smith defended his actions by claiming that the black Rhodesian majority was too inexperienced at the time to participate in the complex administrative process of what was, by contemporary African standards, a reasonably industrialised state. At large, UDI further hardened the white population's attitudes towards majority rule and relations with the UK. A significant majority of white Rhodesian residents were either British immigrants or of British ancestry, and many held a special affection for the British Empire. However, the UK's refusal to grant them independence on their terms further confirmed their opposition to a political settlement on British terms, and fed their negative attitudes towards British interference in Rhodesian politics at large.
Thyroid's secretory capacity (GT, also referred to as SPINA-GT) is the maximum stimulated amount of thyroxine the thyroid can produce in one second. GT is elevated in hyperthyroidism and reduced in hypothyroidism. GT is calculated with
=== Off-label drugs === Antihistamines (histamine H1 receptor antagonists) (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) Corticosteroids (corticosteroid receptor agonists) (e.g., hydrocortisone, prednisone, triamcinolone acetonide) Hydroquinone – tyrosinase inhibitor and skin-lightening agent Nicotinamide (niacinamide) – vitamin B3 Oral antiandrogens (androgen receptor antagonists) (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide, ketoconazole, cimetidine) Other antibiotics (e.g., erythromycin, metronidazole, sulfacetamide) Other ethinylestradiol-containing combined oral contraceptives Salicylic acid – various actions (keratolytic, comedolytic, and bacteriostatic) Zinc – undefined mechanism of action (antibacterial and anti-inflammatory)
Sources: en.wikipedia.org
During the Migration Period, the Jutland peninsula was home to several tribes. The Jutes inhabited the most northern part of the peninsula from Grenen to Olger's Dyke. This dyke, dating back to around the first century, served as the boundary between the Jutes in the north and the Angles in the south. This dyke lost its relevance in the 200s when the Angles expanded northward, leading to the establishment of a new dyke called the Wendish Dyke. The southern border of the Angles was marked by the marshes surrounding the Eider, that combined with the dense old-growth forest to the south of the river, formed a natural barrier. South of the forest lay the region now known as Holstein, which was divided between the Germanic Saxons, who inhabited the western part, and the Slavic Wagri, who lived in the eastern part. In the 8th century, the Wagri became part of the Slavic tribal confederation known as the Obotrites (also known as the Wends by the Danes and Saxons). During the 4th and early 5th centuries, a significant migration saw the Jutes, Angles, and Saxons depart from their homelands to settle in the British Isles. This mass exodus left much of the Jutland Peninsula sparsely populated, allowing the Danes from southern Scandinavia and the islands of Zealand, Funen, and other smaller Danish isles to migrate into the peninsula. They gradually settled the region, integrating the remaining Jutes and Angles who had not left for Britain. By the mid-5th century, the Danes had established settlements from Grenen in the north to just north of the Eider River and its marshes.
In June 2015, Chipotle began test marketing a pork and chicken chorizo-type sausage as a new protein option at selected locations in the Kansas City area. Some food writers have expressed their health related concerns over the protein's relatively high sodium content since a 4-ounce (110 g) serving contains 293 calories and 803 milligrams of sodium while the American Heart Association's recommended daily amount is less than 1,500 milligrams of sodium. In contrast, the protein options with next highest sodium contents are Barbacoa with 530 milligrams and sofritas with 555 milligrams. An earlier version of the Mexican sausage was tested in Denver and New York City in 2011, but that test was terminated when that version of the sausage was perceived as looking too greasy. Chorizo was discontinued in September 2017 but was returned to the menu in the following year for a limited time. In July 2020, Chipotle began test marketing a cauliflower rice option at 55 locations in Colorado and Wisconsin. In August 2021, Chipotle began testing a company-made vegan chorizo made with pea protein. The vegan chorizo (now called plant-based chorizo) was subsequently released nation-wide as a limited-time only item on January 3, 2022, before being removed on March 4, 2022. Chipotle accepts fax orders, and in 2005 the company added the ability to order online from their website. For both online and fax orders, customers proceed to the front of the line to pay for pre-ordered food.
=== Analogues and derivatives === Analogues of 2C-B include 2C-I, 2C-C, DOB, 4C-B, 2C-B-FLY, and 25B-NBOMe, among others. DOB and 4C-B are α-alkyl derivatives of 2C-B, specifically the amphetamine (α-methyl) and phenylisobutylamine (α-ethyl) derivatives, respectively. β-Substituted derivatives of 2C-B such as BOB (β-methoxy-2C-B), BOH-2C-B (β-hydroxy-2C-B), βk-2C-B (β-keto-2C-B), and β-methyl-2C-B (BMB) have been described. βk-2C-B shows dramatically reduced potency and efficacy as a serotonin 5-HT2A receptor agonist compared to 2C-B. A variety of N-substituted derivatives of 2C-B have been tested, including N-methyl-2C-B, N,N-dimethyl-2C-B, N-ethyl-2C-B, and N-benzyl-2C-B. Most simple alkyl derivatives were considerably less potent than 2C-B, with N-ethyl-2C-B for instance having a 40 times lower affinity for the serotonin 5-HT2A receptor. The N-benzyl derivative however was found to have higher affinity than 2C-B itself, with N-(4-bromobenzyl)-2C-B binding even more tightly. This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe, and 25B-NBOH. Another N-substituted derivative, 2C-B-AN, is an N-benzylphenethylamine-like prodrug of 2C-B. 2C-DB (6-bromo-2C-B) is a ring-substituted derivative of 2C-B. TWEETIO derivatives of 2C-B, in which one or both of the methoxy groups of 2C-B are extended to ethoxy groups, exist as well, such as 2CB-2-EtO.
Sources: en.wikipedia.org
== General references == Catholic Encyclopedia Neher in Kirchenlexikon I, 1184–89 De Rubeis, Monumenta Eccles. Aquil. (Strasburg, 1740) Ferdinando Ughelli, Italia Sacra, I sqq.; X, 207 Cappelletti, Chiese d'Italia, VIII, 1 sqq. Menzano, Annali del Friuli (1858–68) Paschini, Sulle Origini della Chiesa di Aquileia (1904) Glaschroeder, in Buchberger's Kirchl. Handl. (Munich, 1904), I, 300-301 Hefele, Conciliengesch. II, 914–23. For the episcopal succession, see P. B. Gams, Series episcoporum (Ratisbon, 1873–86), and Eubel, Hierarchia Catholica Medii Aevi (Muenster, 1898). Glaser, Franz; Pochmarski, Erwin (2012). Aquileia. Der archäologische Führer (in German). Darmstadt/Mainz: Philipp von Zabern. ISBN 978-3-8053-4277-3.
In 1969, Williams made a special effort to instruct Epstein on how to improve as a hitter, with a focus on teaching Epstein to only swing at strikes. That year, Epstein had career highs in batting average, home runs, bases on balls, runs batted in, runs scored, on-base percentage, and slugging percentage. In only 18 more at-bats in 1969 than 1968, he had 17 more home runs, 33 more runs and 52 more RBIs; and his batting average increased from .234 to .278. In 1970, however, Epstein's hitting declined as his average against left-handed pitching fell considerably. In May 1971, he was traded along with Darold Knowles to the Oakland Athletics for Frank Fernandez, Don Mincher, Paul Lindblad, and cash. In 1971, while hitting 18 home runs in 329 at bats, he was hit by a pitch 12 times, leading the league. In 1972 he hit 26 home runs (3rd in the league) for the world champion Athletics. He hit a home run every 17.5 at bats (3rd in the AL), had a .490 slugging percentage (5th), had a .376 on-base percentage (6th), collected 62 walks (10th), and was hit by a pitch 11 times (2nd). He was 16th in voting for the American League MVP. However, in late May, while on the road in Arlington Texas, Epstein and slugger Reggie Jackson came to blows in the clubhouse over Epstein's use of complimentary tickets for family members. The next day, owner Charlie Finley asked him about the incident. Finley claimed Epstein attacked his star player (Jackson). Epstein disputed that, claimed that Jackson was the problem, and demanded to be traded.
In 2012, the Center for Blood Research, which had changed its name to the Immune Disease Institute, merged with Boston Children's Hospital and became the Program in Cellular and Molecular Medicine of Boston Children's Hospital.
Americium-241 (alpha emitter, half-life 432.6 years) is the most common isotope of americium in nuclear waste. It is the isotope used in normal ionization smoke detectors, which work as an ionization chamber. It is a potential fuel for long-lifetime radioisotope thermoelectric generators, with a half-life longer than that of the standard plutonium-238 (87.7 years) or the alternative strontium-90 (28.91 years). Its decay heat is 0.114 W/g; its rate of spontaneous fission 1.2/g/s. The alpha decay of 241Am is accompanied by a significant emission of gamma rays. Its presence in plutonium is determined by the original concentration of 241Pu (which decays to it) and the sample age. Older samples of plutonium containing plutonium-241 build up 241Am, and chemical separation of americium from such plutonium (e.g. during reworking of plutonium pits) may be required.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.